Eyepoint

Eyepoint company information, Employees & Contact Information

Explore related pages

Related company profiles:

EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of people with serious retinal diseases. Our lead product candidate is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining a selective and patent-protected tyrosine kinase inhibitor in next-generation bioerodible technology. Supported by robust safety and efficacy data to date, we are presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration, with topline data anticipated in 2026. We have also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD the leading cause of vision loss among people 50 years of age and older in the United States. We are committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation. Driven by our core values – Transformational Innovation, Unwavering Integrity, Compassionate Excellence, and Inclusive Collaboration, our team is dedicated to achieving our shared vision for the future and bettering the lives of patients, caregivers and healthcare professionals. EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts. Learn more: https://eyepointpharma.com/

Company Details

Employees
213
Address
Watertown, Ma
Phone
617-926-5050
Email
in****@****ida.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Watertown, MA
Looking for a particular Eyepoint employee's phone or email?

Eyepoint Questions

News

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 - EyePoint Pharmaceuticals

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 EyePoint Pharmaceuticals

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration - EyePoint Pharmaceuticals

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration EyePoint Pharmaceuticals

EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint Pharmaceuticals

EyePoint Announces Participation at Upcoming Investor Conferences EyePoint Pharmaceuticals

EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint Pharmaceuticals

EyePoint Announces Participation at Upcoming Investor Conferences EyePoint Pharmaceuticals

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference - EyePoint Pharmaceuticals

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference EyePoint Pharmaceuticals

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints - EyePoint Pharmaceuticals

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints EyePoint Pharmaceuticals

Corporate Governance - EyePoint Pharmaceuticals

Corporate Governance EyePoint Pharmaceuticals

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals

EyePoint to Present at Guggenheim SMID Cap Biotech Conference - EyePoint Pharmaceuticals

EyePoint to Present at Guggenheim SMID Cap Biotech Conference EyePoint Pharmaceuticals

EyePoint Provides Company Update and Anticipated Development Milestones for 2025 - EyePoint Pharmaceuticals

EyePoint Provides Company Update and Anticipated Development Milestones for 2025 EyePoint Pharmaceuticals

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration - EyePoint Pharmaceuticals

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration EyePoint Pharmaceuticals

EyePoint Investor Relations - EyePoint Pharmaceuticals

EyePoint Investor Relations EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4 - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4 EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS) - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS) EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Chief Executive Officer Transition - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Chief Executive Officer Transition EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert® Technology Developments and Provide a Financial Update - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert® Technology Developments and Provide a Financial Update EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Positive Data of YUTIQ® and DEXYCU® in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Positive Data of YUTIQ® and DEXYCU® in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD EyePoint Pharmaceuticals

pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company Will Rebrand as EyePoint Pharmaceuticals, Inc. - EyePoint Pharmaceuticals

pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company Will Rebrand as EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan EyePoint Pharmaceuticals

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting EyePoint Pharmaceuticals

EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCU (dexamethasone intraocular suspension) 9% - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCU (dexamethasone intraocular suspension) 9% EyePoint Pharmaceuticals

pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida's Revenue Generation - EyePoint Pharmaceuticals

pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida's Revenue Generation EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg EyePoint Pharmaceuticals

Top Eyepoint Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant